
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

72402
10.1038/s41598-024-72402-2
Article
Intradialytic oral nutrition effects on malnourished hemodialysis patients: a randomized trial
http://orcid.org/0000-0002-8881-0942
Satirapoj Bancha satirapoj@yahoo.com

Apiyangkool Tanin
Thimachai Paramat
Nata Naowanit
Supasyndh Ouppatham
https://ror.org/007h1qz76 grid.414965.b 0000 0004 0576 1212 Division of Nephrology, Department of Internal Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, 10400 Thailand
13 9 2024
13 9 2024
2024
14 214002 6 2024
6 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Oral nutritional supplementation (ONS) is recommended for malnourished hemodialysis patients when their nutritional intake remains inadequate to meet energy and protein requirements. Patients were randomized into two groups: the intradialytic ONS supplements (INTRA-ONS) group (N = 16) and the interdialytic ONS supplements (INTER-ONS) group (N = 16) for a duration of 12 weeks. Malnutrition inflammation score (MIS) and serum albumin levels were assessed. The total MIS decreased significantly in patients from both the INTRA-ONS group (− 6.13, 95% CI − 8.29 to − 3.96) and the INTER-ONS group (− 3.50, 95% CI − 5.56 to − 1.35). A significant difference in the change of MIS was observed between the two groups (− 3.06, 95% CI − 5.94 to − 0.17). No significant differences were observed between the groups concerning serum albumin levels, dietary intake, anthropometric measurements, or body weight. Intradialytic ONS demonstrates similar benefits on nutritional biomarkers but improves the MIS among malnourished ESRD patients compared to interdialytic ONS.

Trial registration Thai Clinical Trials Registry (TCTR) identification number is TCTR20220322007: 16/09/2021.

Keywords

Intradialytic nutritional supplementation
Interdialytic nutritional supplements
Hemodialysis
Nutrition status
Subject terms

Medical research
Nephrology
issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

A systematic review of compliance with oral nutritional supplements (ONS) among outpatients found that the overall mean compliance is good, especially with higher energy–density ONS; however, the level of cooperation varied, ranging from 30 to 100%1. Consuming less than the targeted amount of nutrients, particularly protein, can lead to malnutrition, disability, and mortality in dialysis patients2. One study indicated that 66.4% of hemodialysis patients consumed fewer than three main meals, and 59.2% reported skipping the same number of snacks on dialysis days3. Malnutrition is particularly pronounced in dialysis patients, where processes such as catabolism, inflammation, and protein loss are heightened4. Consequently, intradialytic meal supplements show that patients meet the targets for treatment-related increases in protein and energy needs5. A Consensus Statement from the International Society of Renal Nutrition and Metabolism suggests that ONS during hemodialysis may be an effective strategy to improve nutritional status, with limited reports of intradialytic complications6.

Data comparing protein metabolism during hemodialysis between intradialytic ONS and intradialytic parenteral nutrition (IDPN), along with a control group, have been examined. Both the Intradialytic ONS and IDPN groups experienced significantly reduced protein loss during hemodialysis compared to the control group. Notably, anabolism increased during hemodialysis in both the intradialytic ONS and IDPN groups, but this effect persisted post-dialysis only in the intradialytic ONS group7. Additionally, the effectiveness of intradialytic ONS in malnourished patients showed increased pre-albumin and albumin levels without complications arising from intradialytic ONS8. However, some studies have indicated that it might increase the risk of intradialytic hypotension9–11. Most of the data utilized originated from descriptive studies, and larger randomized trials are needed12.

To date, limited studies have compared the efficacy of ONS between intra-dialysis (INTRA-ONS group) and alternate-day dialysis (INTER-ONS) among malnourished end-stage kidney disease (ESKD) patients undergoing maintenance hemodialysis. The objective of this study is to compare these data and investigate potential side effects of oral dietary supplements during hemodialysis. Findings from this research will provide valuable insights into the treatment of malnutrition among ESKD patients undergoing hemodialysis.

Material and methods

Study population

Patients undergoing maintenance hemodialysis from September 2021 to March 2022 were included in the study. The inclusion criteria were age > 18 years, patients with ESKD on regular hemodialysis treatment for 4 h, three times weekly for ≥ 6 months, with adequate dialysis as indicated by a single pool Kt/V > 1.2 and a malnutrition inflammation score (MIS) ≥ 6. Exclusion criteria encompassed advanced liver disease, active malignancy, intradialytic hypotension, gut obstruction, gastrointestinal absorption issues, pregnancy or lactation, and recent hospitalization or major surgery within the last 3 months. Discontinuation criteria included unwillingness to continue the study, intolerable side effects, or allergies. The sample size was calculated based on the therapeutic effects of ONS during hemodialysis on changes in serum albumin, as reported in the study by Kayser et al.8 A 5% type I error rate and a 10% type II error rate were used in the calculation. Approximately 32 participants were involved in the research, providing a test power of 80%.

Measurement and outcomes

After screening, patients received standard treatment and dietary counseling from a dietitian. All patients underwent an assessment by a dietitian to ensure they understood self-care principles. Patients were randomly assigned to receive a 370 kcal supplement (80 g) of Once Dialyze (Thai Otsuka Pharmaceutical Co., Ltd., Thailand) during each hemodialysis session, three times per week (INTRA-ONS group), or on days without hemodialysis, three times per week (INTER-ONS group), for 12 weeks, as depicted in Fig. 1. The 80 g supplement is dissolved in 190 mL of water and then adjusted to a final volume of 250 mL before administration. The components of the Once Dialyze supplement, including proteins, carbohydrates with fiber, fats, electrolytes, and micronutrients, are shown in Table 1. Random allocation software was used for randomization with a block size of four.Fig. 1 Study flow of study. INTRA-ONS; intradialytic oral nutritional supplementation, INTER-ONS; interdialytic oral nutritional supplementation.

Table 1 ONCE dialyze formula per serving (370 kcal).

Component	ONCE dialyze	
Caloric distribution of macronutrients (%)	
 Protein	18%	
 Carbohydrate	42%	
 Fat	40%	
Source	
 Protein	16.98 g	
Whey protein isolate 5 g (29.45%)	
Casein 11.98 g (70.55%)	
 Carbohydrate	41.19 g	
Maltodextrin 13.70 g (33.26%)	
Isomaltulose 22.49 g (54.6%)	
Fibersol 2.25 g (5.46%)	
FOS 2.75 g (6.68%)	
 Fat	16.45 g	
Canola oil 4 g (24.32%)	
HOSO 2 g (12.16%)	
MCT oil 5.25 g (31.91%)	
Rice bran oil 5.20 g (31.61%)	
Micronutrient	
 Vitamins and minerals	
 Vitamin A (IU)	70.37	
 Vitamin D (IU)	3.18	
 Vitamin C (mg)	37.48	
 Calcium, mg	149.89	
 Phosphorus, mg	149.89	
 Magnesium, mg	40.81	
 Potassium, mg	206.20	
 Sodium, mg	154.40	
 Carnitine, mg	104.08	
 Others	As Thai RDI recommend	
FOS, fructooligosaccharide; HOSO, high oleic safflower oil; MCT, medium-chain triglyceride; ONCE, Otsuka Nutrition Pharmaceutical; RDI, reference daily intake.

The primary outcome assessed was the change in midweek predialysis serum albumin concentrations at 12 weeks between the INTRA-ONS and INTER-ONS groups. Secondary outcomes included changes in the MIS, dietary protein and energy intake, and body mass index (BMI) between the two groups.

Data collected before and after the study included relevant information on end-stage kidney disease (ESKD), diagnostic criteria, complications, other underlying diseases, comorbidities, medication history, and physical examination parameters such as height, weight, blood pressure, and BMI. The MIS was employed to evaluate the nutritional status of patients undergoing hemodialysis. The MIS assesses various components of nutritional and inflammatory status in patients, including changes in dry weight, dietary intake, gastrointestinal symptoms, functional capacity, fat storage, muscle wasting, co-morbidities, BMI, serum albumin levels, and total iron binding capacity (TIBC). Each component provides critical insights into the patient’s overall health and nutritional needs, particularly in those undergoing hemodialysis. The MIS comprises six anthropometric and laboratory values, each categorized into four severity levels, ranging from 0 (normal) to 3 (severely abnormal), with a total potential score of 3013.

Patients underwent data collection every 4 weeks, and follow-up blood tests were conducted both before and at the end of the study. These tests assessed fasting plasma glucose, serum electrolytes, calcium, phosphate, serum albumin, hemoglobin, blood urea nitrogen, creatinine, single-pool Kt/V, urea reduction ratio (URR), and normalized protein catabolic rate (normalized PCR). Dietary recalls for both dialysis and non-dialysis days were reviewed by a registered dietitian before and after the study period and analyzed for nutrient composition using the standard national food database program (Inmucal, Version 3.2). Adherence to ONS was also assessed through patient self-reports and dietary recalls conducted by a registered dietitian. During each hemodialysis visit, potential side effects were evaluated, and any abnormal symptoms were recorded in a side effects log form.

Ethical considerations

The study adhered to the Declaration of Helsinki (1964). It was registered at the Thai Clinical Trials Registry (TCTR20220322007, dated 16 September 2021). The study protocol received approval from the local Ethics Committee, and written informed consent was obtained from all eligible participants.

Statistical analysis

The intention-to-treat study was analyzed. Categorical variables were described as frequencies, while continuous variables were presented as mean ± standard deviation (SD) if normally distributed. Differences between groups were assessed using independent samples t-tests or Mann–Whitney U tests, and chi-squared tests or Fisher’s exact tests were used for continuous and categorical variables, respectively, as appropriate. Differences within groups were evaluated using paired t-tests. Results were reported as the difference in mean change with a 95% confidence interval (95% CI). A two-sided P-value of 0.05 was considered statistically significant for all analyses. Data analysis was conducted using SPSS for Windows, Version 12 (SPSS, Chicago, IL, USA).

Results

From a screening of a total of 48 patients undergoing regular hemodialysis three times weekly, 16 subjects were excluded. The 32 included patients were randomly divided into two groups, and all were 100% adherent to the ONS supplement. Baseline patient characteristics and laboratory tests categorized by treatment status are summarized in Table 2. Overall, the serum albumin concentration did not differ between the two groups: 3.20 ± 0.23 g/dL in the INTRA-ONS group and 3.27 ± 0.43 g/dL in the INTER-ONS group (P = 0.570). The MIS score was also similar in both groups: 12.94 ± 4.46 in the INTRA-ONS group versus 11.13 ± 4.21 in the INTER-ONS group (P = 0.247). The baseline characteristics of the two groups did not differ concerning age, gender, comorbid diseases, BMI, dietary protein and energy intake, and adequacy of dialysis.Table 2 Baseline characteristics.

Characteristics	INTRA-ONS
(N = 16)	INTER-ONS
(N = 16)	P value	
Age (years)	72.3 ± 7.9	72.7 ± 7.9	0.894	
Male (%)	8 (50%)	8 (50%)	1.000	
Comorbid diseases, N (%)	
 Type 2 diabetes	5 (31.3%)	7 (43.8%)	0.465	
 Hypertension	14 (87.5%)	11 (68.8%)	1.000	
 Dyslipidemia	9 (56.3%)	6 (37.5%)	0.288	
 Cardiovascular disease	7 (43.8)	9 (56.3)	1.000	
Systolic blood pressure (mmHg)	131.5 ± 19.3	131.3 ± 24.5	0.981	
Diastolic blood pressure (mmHg)	70.3 ± 10.0	64.0 ± 12.9	0.134	
Dietary energy intake (kcal/day)	1265.3 ± 374.5	1152.1 ± 248.5	0.322	
Dietary protein intake (g/day)	52.8 ± 16.7	48.3 ± 12.9	0.396	
Hemoglobin (g/dL)	10.6 ± 1.8	9.7 ± 2.1	0.235	
Single pool Kt/V	1.8 ± 0.3	1.8 ± 0.3	0.711	
High flux hemodialysis	16 (100%)	16 (100%)	1.000	
AV access			0.874	
 Arteriovenous fistula	9 (56.3%)	10 (62.5%)		
 Arteriovenous graft	7 (43.7%)	6 (37.5%)		
Normalized protein catabolic state (PCR) (g/day)	1.1 ± 0.3	1.0 ± 0.3	0.753	
Blood glucose (mg/dL)	121.4 ± 40.4	118.9 ± 28.5	0.845	
Blood urea nitrogen (mg/dL)	50.7 ± 15.1	49.6 ± 17.8	0.846	
Serum creatinine (mg/dL)	7.4 ± 2.2	7.2 ± 2.0	0.799	
Serum albumin (g/dL)	3.2 ± 0.2	3.3 ± 0.4	0.570	
Serum potassium (mg/dL)	3.9 ± 0.7	4.0 ± 0.8	0.510	
Serum phosphate (mg/dL)	3.9 ± 1.0	3.9 ± 1.2	0.952	
Absolute lymphocyte count (cells)	1405.6 ± 409.6	1377.2 ± 706.4	0.890	
High sensitivity-CRP (mg/L)	6.4 ± 2.2	6.8 ± 1.8	0.459	
MIS score	12.9 ± 4.5	11.1 ± 4.2	0.247	
Data in the table are shown with mean ± standard deviation and percentage.

Change of nutritional parameters during the study

The mean change in serum albumin from baseline was 0.23 (95% CI 0.04–0.43, P = 0.024) in the INTRA-ONS group and 0.19 (95% CI 0.07–0.31, P = 0.003) in the INTER-ONS group. At 12 weeks, no significant mean difference in serum albumin levels (0.04, 95% CI − 0.18 to 0.26) was found between the two groups, as shown in Fig. 2 and Table 3. Similarly, there were no significant differences in blood urea nitrogen, creatinine, daily calorie intake, dialysis protein intake, normalized PCR, body weight and BMI between the two groups, as shown in Table 3.Fig. 2 Change in serum albumin and MIS level during the study.

Table 3 Outcomes between INTRA-ONS and INTER-ONS groups.

	INTRA-ONS
(N = 16)	INTER-ONS
(N = 16)	Mean difference
(95% CI)	 P-value	
Serum albumin (g/dL)	
 Baseline	3.2 ± 0.2	3.3 ± 0.4	− 0.07 (− 0.33, 0.18)	0.570	
 At 12-week	3.4 ± 0.4	3.4 ± 0.4	− 0.01 (− 0.32, 0.29)	0.939	
 Mean change (95% CI)	0.23 (0.04, 0.43)	0.19 (0.07, 0.31)	0.04 (− 0.18, 0.26)	0.730	
 P-value	0.024	0.003			
Blood urea nitrogen (mg/dL)	
 Baseline	50.7 ± 15.1	49.6 ± 17.8	1.18 (− 11.09, 13.45)	0.846	
 At 12-week	55.7 ± 14.4	48.5 ± 11.7	7.25 (− 2.66, 17.17)	0.145	
 Mean change (95% CI)	5.0 (− 3.35, 13.35)	− 1.08 (− 11.79, 9.64)	6.08 (− 6.72, 18.88))	0.339	
 P-value	0.221	0.831			
Serum creatinine (mg/dL)	
 Baseline	7.4 ± 2.2	7.2 ± 2.0	0.19 (− 1.38, 1.78)	0.799	
 At 12-week	7.7 ± 1.9	6.8 ± 2.2	0.89 (− 0.63, 2.42)	0.239	
 Mean change (95% CI)	0.34 (− 0.37, 1.06)	− 0.35 (− 1.12, 0.42)	0.69 (− 0.31, 1.70)	0.168	
 P-value	0.323	0.345			
MIS score	
 Baseline	12.9 ± 4.5	11.1 ± 4.2	1.81 (− 1.32, 4.95)	0.247	
 At 12-week	6.8 ± 4.3	7.7 ± 1.9	− 0.81 (− 3.46, 1.84)	0.536	
 Mean change (95% CI)	− 6.13 (− 8.29, − 3.96)	− 3.5 (− 5.56, − 1.35)	− 3.06 (− 5.94, − 0.17)	0.038	
 P-value	0.000023	0.003			
Dietary energy intake (kcal/day)	
 Baseline	1265.3 ± 374.5	1152.1 ± 248.5	113.18 (− 116.32, 342.67)	0.322	
 At 12-week	1173.1 ± 297.2	1091.8 ± 302.3	81.29 (− 135.14, 297.71)	0.449	
 Mean change (95% CI)	− 92.19 (− 243.42, 59.03)	− 60.31 (− 223.55, 102.94)	− 31.89 (− 245.16, 181.33)	0.762	
 P-value	0.213	0.443			
Dietary protein intake (g/day)	
 Baseline	52.8 ± 16.7	48.3 ± 12.9	4.54 (− 6.23, 15.31)	0.396	
 At 12-week	47.6 ± 16.0	42.3 ± 11.3	5.25 (− 4.76, 15.26)	0.293	
 Mean change (95% CI)	− 5.56 (− 12.14, 1.62)	− 5.97 (− 12.91, 0.97)	0.71 (− 8.65, 10.07)	0.878	
 P-value	0.124	0.087			
Normalized protein catabolic state (PCR) (g/day)	
 Baseline	1.1 ± 0.3	1.0 ± 0.3	0.03 (− 0.17, 0.23)	0.753	
 At 12-week	1.2 ± 0.3	1.1 ± 0.2	0.14 (− 0.06, 0.33)	0.160	
 Mean change (95% CI)	0.16 (0.01, 0.32)	0.06 (− 0.05, 0.16)	0.11 (− 0.08, 0.29)	0.241	
 P-value	0.043	0.278			
Body weight (kg)	
 Baseline	50.8 ± 6.9	53.9 ± 8.8	− 3.03 (− 8.74, 2.69)	0.289	
 At 12-week	51.8 ± 6.9	54.1 ± 8.3	− 2.28 (− 7.79, 3.23)	0.404	
 Mean change (95% CI)	0.98 (0.36, 1.60)	0.24 (− 1.18, 1.65)	0.74 (− 0.76, 2.25)	0.316	
 P-value	0.004	0.725			
BMI (kg/m2)	
 Baseline	20.0 ± 2.5	21.0 ± 2.3	− 1.00 (− 2.72, 0.71)	0.242	
 At 12-week	20.4 ± 2.7	21.2 ± 2.0	− 0.75 (− 2.44, 0.95)	0.377	
 Mean change (95% CI)	0.41 (0.17, 0.64)	0.15 (− 0.43, 0.73)	0.26 (− 0.36, 0.87)	0.393	
 P-value	0.003	0.594			
Systolic blood pressure (mmHg)	
 Baseline	131.5 ± 19.3	131.3 ± 24.5	0.19 (− 15.73, 16.10)	0.981	
 At 12-week	136.6 ± 20.9	140.4 ± 24.4	− 3.81 (− 20.21, 12.59)	0.638	
 Mean change (95% CI)	5.06 (− 8.41, 18.53)	9.06 (− 10.23, 28.35)	− 4.00 (− 26.54, 18.54)	0.720	
 P-value	0.436	0.333			
 Diastolic blood pressure (mmHg)	
 Baseline	70.3 ± 10.0	64.0 ± 12.9	6.31 (− 2.04, 14.67)	0.134	
 At 12-week	70.7 ± 9.7	66.8 ± 11.3	3.88 (− 3.71, 11.46)	0.305	
 Mean change (95% CI)	0.38 (− 5.52, 6.27)	2.81 (− 6.50, 12.13)	− 2.44 (− 13.00, 8.13)	0.641	
 P-value	0.894	0.53			
Data in the table are shown with mean ± standard deviation and median with interquartile range and mean change with 95% confidence interval (CI), *P < 0.05.

Interestingly, the malnutrition score using MIS significantly decreased in both the INTRA-ONS group [− 6.13 (95% CI − 8.29 to − 3.96), P < 0.001] and the INTER-ONS group [− 3.5 (95% CI − 5.56 to − 1.35), P = 0.003], as shown in Table 3. At 12 weeks, changes in the MIS significantly differed between the two groups [− 3.06 (95% CI − 5.94 to − 0.17), P = 0.038] (Fig. 2).

Adverse events after treatment

After 12 weeks, changes in blood glucose, pre- and post-dialysis blood pressure, and adequacy of dialysis did not significantly differ between the two groups (Table 3). Serum potassium and phosphate levels also showed no significant changes between the groups. No serious adverse events were observed, including severe abdominal pain, diarrhea, or serious electrolyte disturbances, in either group during the study period. Two patients experienced intradialytic hypotension, one patient experienced nausea, and one patient experienced diarrhea during ONS administration during hemodialysis. Meanwhile, one patient experienced intradialytic hypotension, two patients experienced nausea, and one patient experienced vomiting during ONS administration on non-dialysis days. None of the patients were forced to drop out of the study due to adverse effects from the treatment.

Discussion

The first randomized controlled trial investigated the efficacy of ONS supplement during hemodialysis versus on days without hemodialysis in ESKD patients undergoing hemodialysis with malnutrition. At 12 weeks of treatment, there was no significant difference in nutrition biomarkers, including serum albumin, dietary protein, and energy intake, blood urea nitrogen, and body composition between the INTRA-ONS and INTER-ONS groups, except for a significantly greater reduction in MIS in the INTRA-ONS group. No significant adverse events were observed between the two groups.

Current guideline has documented the importance of inadequate dietary protein and energy intake in ESKD patients undergoing hemodialysis14. Inadequate dietary intake contributes to decreased anabolism, and the dialysis procedure further exacerbates the negative nitrogen and energy balance due to amino acid losses into the dialysate15. Unfortunately, dietary counseling is not always successful in the ESKD population16. Meta-analysis has confirmed that nutrient supplementation during or after hemodialysis offers several benefits to patients, including increased energy, protein, and micronutrient intake, improved muscle strength, quality of life, and prevention and treatment of malnutrition17. Flexibility in administration allows ONS to be provided in various forms and timings for personalized care based on dietary preferences. Our study demonstrated some positive benefits of ONS during or after hemodialysis on nutritional status, including serum albumin, body weight, BMI and dietary nutrient intake.

The MIS is a tool used to assess the nutritional status of patients undergoing hemodialysis and has been shown to be a strong predictor of quality of life and mortality13,18. Therefore, appropriate therapeutic nutritional interventions are crucial for improving outcomes in hemodialysis patients19 Some studies suggest that interventions to improve nutritional status can also enhance inflammation and physical performance19,20. Each 2-unit increase in MIS is associated with a twofold greater risk of death in hemodialysis patients13. Previous studies found that intradialytic ONS combined with dietary counseling was more effective than dietary counseling alone in improving nutritional status and inflammation in chronic hemodialysis patients21–24. Our study also indicated that the effect of INTRA-ONS with a decrease in the MIS at 3 points might benefit hemodialysis patients with malnutrition compared to the INTER-ONS group.

Factors contributing to the greater reduction of MIS in the INTRA-ONS group may be related to the persistence of anabolism during and after hemodialysis. Studies have supported our finding that ONS during dialysis improves skeletal muscle protein homeostasis7 and prevents catabolism associated with dialysis25. Additionally, ONS may reduce inflammation, as ongoing inflammation can be exacerbated by declining nutritional status26. Renal-specific formulas and fat-based energy-dense supplements may effectively prevent energy deficits, improve inflammation, and dietary intake among ESKD patients on dialysis21–24. However, evidence regarding the effects of ONS during dialysis on nutritional status remains limited, necessitating further large-scale, high-quality studies.

Eating during hemodialysis can have both positive and negative effects on blood pressure. Some studies indicate that intradialytic food intake can negatively impact the postprandial blood pressure response27,28. However, other studies report no relationship between food intake and blood pressure during hemodialysis29. Several factors contribute to hemodialysis hypotension, including the reduction of circulating blood volume and sodium uptake. Our study found no significant relationship between eating during hemodialysis and blood pressure changes, and no serious adverse events were reported with ONS in either study group. However, there was an observed increase in systolic blood pressure by 10 mmHg in the INTER-ONS group. Factors that may have contributed to this finding include the consumption of ONS on non-dialysis days, which may have resulted in greater fluid intake and subsequent fluid retention, leading to increased blood volume and blood pressure. Patients in the INTER-ONS group may have had difficulty adhering to fluid restrictions on non-dialysis days when supplements were provided.

The study encountered several limitations. First, it was limited to a small, single-center design with a short follow-up period, which prevents drawing conclusions about the long-term effects of ONS during dialysis on the reduction MIS and related nutritional, metabolic, and inflammatory issues. However, the follow-up duration of up to 12 weeks was still deemed effective for observing significant changes in nutritional status and adherence to dietary plans30. Therefore, the long-term efficacy and safety of ONS during dialysis require further investigation. Second, we did not measure changes in other protein catabolism states and inflammatory biomarkers during treatment, and mechanistic associations between ONS during hemodialysis and overall nutritional changes in ESKD were not assessed.

In conclusion, ONS administration during dialysis in ESRD patients shows similar effects on overall nutritional biomarkers but produces lower MIS levels than controls after 12 weeks of treatment. Our findings suggest the therapeutic potential of ONS during hemodialysis in the ESRD population. Further study is necessary to determine the long-term effects of intradialytic ONS supplementation on the prevalence of malnutrition, hospitalization, and mortality among ESRD patients due to decreased MIS levels.

Acknowledgements

The authors wish to thank the staff in the Division of Nephrology, Department of Medicine, Phramongkutklao Hospital and College of Medicine, for their research contributions.

Author contributions

T.A. and B.S. conceived the research idea and study design and performed data acquisition as well as data analysis/interpretation. T.A., P.T., N.N., O.S. and B.S. performed data acquisition. O.S. and B.S. supervised the work and provided mentorship. B.S. takes responsibility that this study has been reported honestly, accurately, and transparently and accepts the accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

Data availability

All relevant data are within the paper.

Competing interests

The authors declare no competing interests.

Ethics statement

The study protocol was approved by the Ethics Committee of the Institute Review Board of the Royal Thai Army Medical Department (R103h/64).

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Hubbard GP Elia M Holdoway A Stratton RJ A systematic review of compliance to oral nutritional supplements Clin. Nutr. 2012 31 3 293 312 10.1016/j.clnu.2011.11.020 22257636
Hubbard, G. P., Elia, M., Holdoway, A. & Stratton, R. J. A systematic review of compliance to oral nutritional supplements. Clin. Nutr. 31(3), 293–312. 10.1016/j.clnu.2011.11.020 (2012).22257636 10.1016/j.clnu.2011.11.020
2. Lacquaniti A Bolignano D Campo S Perrone C Donato V Fazio MR Buemi A Sturiale A Buemi M Malnutrition in the elderly patient on dialysis Ren. Fail. 2009 31 3 239 245 10.1080/08860220802669891 19288330
Lacquaniti, A. et al. Malnutrition in the elderly patient on dialysis. Ren. Fail. 31(3), 239–245. 10.1080/08860220802669891 (2009).19288330 10.1080/08860220802669891
3. Badrasawi M Zidan S Sharif I Qaisiyha J Ewaida S Jaradat T Samamra Y Prevalence and correlates of malnutrition among hemodialysis patients at hebron governmental hospital, Palestine: Cross-sectional study BMC Nephrol. 2021 22 1 214 10.1186/s12882-021-02413-y 34098899
Badrasawi, M. et al. Prevalence and correlates of malnutrition among hemodialysis patients at hebron governmental hospital, Palestine: Cross-sectional study. BMC Nephrol. 22(1), 214. 10.1186/s12882-021-02413-y (2021).34098899 10.1186/s12882-021-02413-y
4. Carrero JJ Stenvinkel P Cuppari L Ikizler TA Kalantar-Zadeh K Kaysen G Mitch WE Price SR Wanner C Wang AY ter Wee P Franch HA Etiology of the protein-energy wasting syndrome in chronic kidney disease: A consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM) J. Ren. Nutr. 2013 23 2 77 90 10.1053/j.jrn.2013.01.001 23428357
Carrero, J. J. et al. Etiology of the protein-energy wasting syndrome in chronic kidney disease: A consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J. Ren. Nutr. 23(2), 77–90. 10.1053/j.jrn.2013.01.001 (2013).23428357 10.1053/j.jrn.2013.01.001
5. Martins VS Adragao T Aguiar L Fortes A Costa M Borges N Calhau C Macario F Can an intradialytic snack model compensate the catabolic impact of hemodialysis? Clin. Nutr. ESPEN 2021 42 292 298 10.1016/j.clnesp.2021.01.018 33745595
Martins, V. S. et al. Can an intradialytic snack model compensate the catabolic impact of hemodialysis?. Clin. Nutr. ESPEN 42, 292–298. 10.1016/j.clnesp.2021.01.018 (2021).33745595 10.1016/j.clnesp.2021.01.018
6. Kistler BM Benner D Burrowes JD Campbell KL Fouque D Garibotto G Kopple JD Kovesdy CP Rhee CM Steiber A Stenvinkel P Ter Wee P Teta D Wang AYM Kalantar-Zadeh K Eating during hemodialysis treatment: A consensus statement from the international society of renal nutrition and metabolism J. Ren. Nutr. 2018 28 1 4 12 10.1053/j.jrn.2017.10.003 29249295
Kistler, B. M. et al. Eating during hemodialysis treatment: A consensus statement from the international society of renal nutrition and metabolism. J. Ren. Nutr. 28(1), 4–12. 10.1053/j.jrn.2017.10.003 (2018).29249295 10.1053/j.jrn.2017.10.003
7. Pupim LB Majchrzak KM Flakoll PJ Ikizler TA Intradialytic oral nutrition improves protein homeostasis in chronic hemodialysis patients with deranged nutritional status J. Am. Soc. Nephrol. 2006 17 11 3149 3157 10.1681/ASN.2006040413 17021267
Pupim, L. B., Majchrzak, K. M., Flakoll, P. J. & Ikizler, T. A. Intradialytic oral nutrition improves protein homeostasis in chronic hemodialysis patients with deranged nutritional status. J. Am. Soc. Nephrol. 17(11), 3149–3157. 10.1681/ASN.2006040413 (2006).17021267 10.1681/ASN.2006040413
8. Caglar K Fedje L Dimmitt R Hakim RM Shyr Y Ikizler TA Therapeutic effects of oral nutritional supplementation during hemodialysis Kidney Int. 2002 62 3 1054 1059 10.1046/j.1523-1755.2002.00530.x 12164890
Caglar, K. et al. Therapeutic effects of oral nutritional supplementation during hemodialysis. Kidney Int. 62(3), 1054–1059. 10.1046/j.1523-1755.2002.00530.x (2002).12164890 10.1046/j.1523-1755.2002.00530.x
9. Zoccali C Mallamaci F Ciccarelli M Maggiore Q Postprandial alterations in arterial pressure control during hemodialysis in uremic patients Clin. Nephrol. 1989 31 6 323 326 2752600
Zoccali, C., Mallamaci, F., Ciccarelli, M. & Maggiore, Q. Postprandial alterations in arterial pressure control during hemodialysis in uremic patients. Clin. Nephrol. 31(6), 323–326 (1989).2752600
10. Agarwal R Georgianos P Feeding during dialysis-risks and uncertainties Nephrol. Dial. Transplant. 2018 33 6 917 922 10.1093/ndt/gfx195 28633456
Agarwal, R. & Georgianos, P. Feeding during dialysis-risks and uncertainties. Nephrol. Dial. Transplant. 33(6), 917–922. 10.1093/ndt/gfx195 (2018).28633456 10.1093/ndt/gfx195
11. Choi MS Kistler B Wiese GN Stremke ER Wright AJ Moorthi RN Moe SM Hill Gallant KM Pilot study of the effects of high-protein meals during hemodialysis on intradialytic hypotension in patients undergoing maintenance hemodialysis J. Ren. Nutr. 2019 29 2 102 111 10.1053/j.jrn.2018.06.002 30107974
Choi, M. S. et al. Pilot study of the effects of high-protein meals during hemodialysis on intradialytic hypotension in patients undergoing maintenance hemodialysis. J. Ren. Nutr. 29(2), 102–111. 10.1053/j.jrn.2018.06.002 (2019).30107974 10.1053/j.jrn.2018.06.002
12. Kistler B Benner D Burgess M Stasios M Kalantar-Zadeh K Wilund KR To eat or not to eat-international experiences with eating during hemodialysis treatment J. Ren. Nutr. 2014 24 6 349 352 10.1053/j.jrn.2014.08.003 25443543
Kistler, B. et al. To eat or not to eat-international experiences with eating during hemodialysis treatment. J. Ren. Nutr. 24(6), 349–352. 10.1053/j.jrn.2014.08.003 (2014).25443543 10.1053/j.jrn.2014.08.003
13. Rambod M Bross R Zitterkoph J Benner D Pithia J Colman S Kovesdy CP Kopple JD Kalantar-Zadeh K Association of Malnutrition-Inflammation Score with quality of life and mortality in hemodialysis patients: A 5-year prospective cohort study Am. J. Kidney Dis. 2009 53 2 298 309 10.1053/j.ajkd.2008.09.018 19070949
Rambod, M. et al. Association of Malnutrition-Inflammation Score with quality of life and mortality in hemodialysis patients: A 5-year prospective cohort study. Am. J. Kidney Dis. 53(2), 298–309. 10.1053/j.ajkd.2008.09.018 (2009).19070949 10.1053/j.ajkd.2008.09.018
14. Fiaccadori E Sabatino A Barazzoni R Carrero JJ Cupisti A De Waele E Jonckheer J Singer P Cuerda C ESPEN guideline on clinical nutrition in hospitalized patients with acute or chronic kidney disease Clin. Nutr. 2021 40 4 1644 1668 10.1016/j.clnu.2021.01.028 33640205
Fiaccadori, E. et al. ESPEN guideline on clinical nutrition in hospitalized patients with acute or chronic kidney disease. Clin. Nutr. 40(4), 1644–1668. 10.1016/j.clnu.2021.01.028 (2021).33640205 10.1016/j.clnu.2021.01.028
15. Ikizler TA Pupim LB Brouillette JR Levenhagen DK Farmer K Hakim RM Flakoll PJ Hemodialysis stimulates muscle and whole body protein loss and alters substrate oxidation Am. J. Physiol. Endocrinol. Metab. 2002 282 1 E107 E116 10.1152/ajpendo.2002.282.1.E107 11739090
Ikizler, T. A. et al. Hemodialysis stimulates muscle and whole body protein loss and alters substrate oxidation. Am. J. Physiol. Endocrinol. Metab. 282(1), E107–E116. 10.1152/ajpendo.2002.282.1.E107 (2002).11739090 10.1152/ajpendo.2002.282.1.E107
16. Dwyer JT Cunniff PJ Maroni BJ Kopple JD Burrowes JD Powers SN Cockram DB Cameron Chumlea W Kusek JW Makoff R Jordi Goldstein D Paranandi L The hemodialysis pilot study: nutrition program and participant characteristics at baseline J. Ren. Nutr. 1998 8 1 11 20 10.1016/S1051-2276(98)90032-2 9724825
Dwyer, J. T. et al. The hemodialysis pilot study: nutrition program and participant characteristics at baseline. J. Ren. Nutr. 8(1), 11–20. 10.1016/S1051-2276(98)90032-2 (1998).9724825 10.1016/S1051-2276(98)90032-2
17. Liu PJ Guo J Zhang Y Wang F Yu K Effects of oral nutritional supplements on the nutritional status and inflammatory markers in patients on maintenance dialysis: A systematic review and meta-analysis of randomized clinical trials Clin. Kidney J. 2023 16 11 2271 2288 10.1093/ckj/sfad130 37915917
Liu, P. J., Guo, J., Zhang, Y., Wang, F. & Yu, K. Effects of oral nutritional supplements on the nutritional status and inflammatory markers in patients on maintenance dialysis: A systematic review and meta-analysis of randomized clinical trials. Clin. Kidney J. 16(11), 2271–2288. 10.1093/ckj/sfad130 (2023).37915917 10.1093/ckj/sfad130
18. Sa Martins V Adragao T Aguiar L Pinto I Dias C Figueiredo R Lourenco P Pascoal T Pereira J Pinheiro T Ramiao I Velez B Papoila AL Borges N Calhau C Macario F Prognostic value of the malnutrition-inflammation score in hospitalization and mortality on long-term hemodialysis J. Ren. Nutr. 2022 32 5 569 577 10.1053/j.jrn.2021.11.002 34922814
Sa Martins, V. et al. Prognostic value of the malnutrition-inflammation score in hospitalization and mortality on long-term hemodialysis. J. Ren. Nutr. 32(5), 569–577. 10.1053/j.jrn.2021.11.002 (2022).34922814 10.1053/j.jrn.2021.11.002
19. Alp Ikizler T Cano NJ Franch H Fouque D Himmelfarb J Kalantar-Zadeh K Kuhlmann MK Stenvinkel P TerWee P Teta D Wang AY-M Wanner C Prevention and treatment of protein energy wasting in chronic kidney disease patients: A consensus statement by the International Society of Renal Nutrition and Metabolism Kidney Int. 2013 84 6 1096 1107 10.1038/ki.2013.147 23698226
Alp Ikizler, T. et al. Prevention and treatment of protein energy wasting in chronic kidney disease patients: A consensus statement by the International Society of Renal Nutrition and Metabolism. Kidney Int. 84(6), 1096–1107. 10.1038/ki.2013.147 (2013).23698226 10.1038/ki.2013.147
20. Kanda E Lopes MB Tsuruya K Hirakata H Iseki K Karaboyas A Bieber B Jacobson SH Dasgupta I Robinson BM The combination of malnutrition-inflammation and functional status limitations is associated with mortality in hemodialysis patients Sci. Rep. 2021 11 1 1582 10.1038/s41598-020-80716-0 33452326
Kanda, E. et al. The combination of malnutrition-inflammation and functional status limitations is associated with mortality in hemodialysis patients. Sci. Rep. 11(1), 1582. 10.1038/s41598-020-80716-0 (2021).33452326 10.1038/s41598-020-80716-0
21. Yang Y Qin X Chen J Wang Q Kong Y Wan Q Tao H Liu A Li Y Lin Z Huang Y He Y Lei Z Liang M The effects of oral energy-dense supplements on nutritional status in nondiabetic maintenance hemodialysis patients: A randomized controlled trial Clin. J. Am. Soc. Nephrol. 2021 16 8 1228 1236 10.2215/CJN.16821020 34155082
Yang, Y. et al. The effects of oral energy-dense supplements on nutritional status in nondiabetic maintenance hemodialysis patients: A randomized controlled trial. Clin. J. Am. Soc. Nephrol. 16(8), 1228–1236. 10.2215/CJN.16821020 (2021).34155082 10.2215/CJN.16821020
22. Satirapoj B Limwannata P Kleebchaiyaphum C Prapakorn J Yatinan U Chotsriluecha S Supasyndh O Nutritional status among peritoneal dialysis patients after oral supplement with ONCE dialyze formula Int. J. Nephrol. Renovasc. Dis. 2017 10 145 151 10.2147/IJNRD.S138047 28652800
Satirapoj, B. et al. Nutritional status among peritoneal dialysis patients after oral supplement with ONCE dialyze formula. Int. J. Nephrol. Renovasc. Dis. 10, 145–151. 10.2147/IJNRD.S138047 (2017).28652800 10.2147/IJNRD.S138047
23. Limwannata P Satirapoj B Chotsriluecha S Thimachai P Supasyndh O Effectiveness of renal-specific oral nutritional supplements compared with diet counseling in malnourished hemodialysis patients Int. Urol. Nephrol. 2021 53 8 1675 1687 10.1007/s11255-020-02768-5 33452957
Limwannata, P., Satirapoj, B., Chotsriluecha, S., Thimachai, P. & Supasyndh, O. Effectiveness of renal-specific oral nutritional supplements compared with diet counseling in malnourished hemodialysis patients. Int. Urol. Nephrol. 53(8), 1675–1687. 10.1007/s11255-020-02768-5 (2021).33452957 10.1007/s11255-020-02768-5
24. Tomayko EJ Kistler BM Fitschen PJ Wilund KR Intradialytic protein supplementation reduces inflammation and improves physical function in maintenance hemodialysis patients J. Ren. Nutr. 2015 25 3 276 283 10.1053/j.jrn.2014.10.005 25455421
Tomayko, E. J., Kistler, B. M., Fitschen, P. J. & Wilund, K. R. Intradialytic protein supplementation reduces inflammation and improves physical function in maintenance hemodialysis patients. J. Ren. Nutr. 25(3), 276–283. 10.1053/j.jrn.2014.10.005 (2015).25455421 10.1053/j.jrn.2014.10.005
25. Veeneman JM Kingma HA Boer TS Stellaard F De Jong PE Reijngoud DJ Huisman RM Protein intake during hemodialysis maintains a positive whole body protein balance in chronic hemodialysis patients Am. J. Physiol. Endocrinol. Metab. 2003 284 5 E954 E965 10.1152/ajpendo.00264.2002 12540372
Veeneman, J. M. et al. Protein intake during hemodialysis maintains a positive whole body protein balance in chronic hemodialysis patients. Am. J. Physiol. Endocrinol. Metab. 284(5), E954–E965. 10.1152/ajpendo.00264.2002 (2003).12540372 10.1152/ajpendo.00264.2002
26. Wright S Weiner DE Oral nutritional supplement use in dialysis patients: Full speed ahead? Am. J. Kidney Dis. 2012 60 4 507 509 10.1053/j.ajkd.2012.07.004 22985978
Wright, S. & Weiner, D. E. Oral nutritional supplement use in dialysis patients: Full speed ahead?. Am. J. Kidney Dis. 60(4), 507–509. 10.1053/j.ajkd.2012.07.004 (2012).22985978 10.1053/j.ajkd.2012.07.004
27. Avci M Arikan F The effect of food intake during hemodialysis on blood pressure: A nonrandomized experimental trial Ther. Apher. Dial 2023 27 4 661 668 10.1111/1744-9987.13967 36606660
Avci, M. & Arikan, F. The effect of food intake during hemodialysis on blood pressure: A nonrandomized experimental trial. Ther. Apher. Dial 27(4), 661–668. 10.1111/1744-9987.13967 (2023).36606660 10.1111/1744-9987.13967
28. Sivalingam M Banerjee A Nevett G Farrington K Haemodynamic effects of food intake during haemodialysis Blood Purif. 2008 26 2 157 162 10.1159/000114094 18230971
Sivalingam, M., Banerjee, A., Nevett, G. & Farrington, K. Haemodynamic effects of food intake during haemodialysis. Blood Purif. 26(2), 157–162. 10.1159/000114094 (2008).18230971 10.1159/000114094
29. Benaroia M Iliescu EA Oral intake during hemodialysis: Is there an association with intradialytic hypotension? Hemodial. Int. 2008 12 1 62 65 10.1111/j.1542-4758.2008.00242.x 18271843
Benaroia, M. & Iliescu, E. A. Oral intake during hemodialysis: Is there an association with intradialytic hypotension?. Hemodial. Int. 12(1), 62–65. 10.1111/j.1542-4758.2008.00242.x (2008).18271843 10.1111/j.1542-4758.2008.00242.x
30. Ingstad K Uhrenfeldt L Kymre IG Skrubbeltrang C Pedersen P Effectiveness of individualised nutritional care plans to reduce malnutrition during hospitalisation and up to 3 months post-discharge: A systematic scoping review BMJ Open 2020 10 11 e040439 10.1136/bmjopen-2020-040439 33148761
Ingstad, K., Uhrenfeldt, L., Kymre, I. G., Skrubbeltrang, C. & Pedersen, P. Effectiveness of individualised nutritional care plans to reduce malnutrition during hospitalisation and up to 3 months post-discharge: A systematic scoping review. BMJ Open 10(11), e040439. 10.1136/bmjopen-2020-040439 (2020).33148761 10.1136/bmjopen-2020-040439
